Pablo A. R.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase II Evaluation of Eribulin and Izorlisib Mesilate in Advanced PIK3CA/PTEN-Altered Triple Negative and HR-Positive/HER2-Negative Breast Cancer
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Elacestrant and Everolimus in ER+/HER2-, ESR1-Mutated Advanced Breast Cancer Post-Endocrine and CDK4/6 Inhibitors
Data & Insights
Has run more than one trial at 5 of 91 partner sites.
Specializations
Oncology Focus
The investigator specializes in the treatment of advanced breast cancer, with particular emphasis on hormone receptor-positive disease. Their research concentrates on addressing therapeutic challenges in estrogen receptor-positive breast cancer.
- Hormone Receptor-Positive Breast Cancer
- ESR1-Mutated Cancer Research
- Advanced Disease Management
Their work encompasses innovative approaches for patients whose disease has progressed following standard treatments.
Therapeutic Innovation
The investigator focuses on developing treatment strategies for patients with HER2-negative breast cancer. Their expertise includes investigating novel therapeutic combinations targeting specific molecular pathways.
- Endocrine Therapy Resistance
- Targeted Therapy Combinations
- Molecular Pathway Research
Their research addresses critical needs in overcoming treatment resistance in advanced breast cancer.
Clinical Advancement
The investigator's work centers on precision medicine approaches in breast cancer treatment, particularly for patients who have progressed on established therapies. They explore new treatment paradigms for resistant disease.
- Treatment-Resistant Disease
- Novel Therapeutic Strategies
- Advanced Cancer Care
Their research aims to expand treatment options for patients with limited therapeutic alternatives.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.